Clinical trial
Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human…
NCT00289172 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00289172 |
|---|---|
| Title | Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India |
| Official title | A Multicenter Study of the Immunogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine (RIX4414) as Primary Dosing of Healthy Infants in India Aged Approximately 8 Wks at the Time of the First Dose |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Rotavirus |
| Intervention type | Biological |
| Interventions | Live attenuated human rotavirus vaccine |
| Enrollment | 360 |
| Start date | Feb 10, 2006 |
| Completion | Sep 8, 2006 |
| First posted | Feb 9, 2006 |
| Last update posted | May 30, 2017 |
| Countries | India |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: